AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Alpha/beta hydrolase domain-containing protein 17A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96GS6

UPID:

AB17A_HUMAN

Alternative names:

-

Alternative UPACC:

Q96GS6; A8K0G8; D6W5Z9; Q6PJU2; Q8WUH9; Q9BWL0; Q9H7Q9

Background:

Alpha/beta hydrolase domain-containing protein 17A, identified by the accession number Q96GS6, plays a crucial role in cellular processes through its enzymatic activity. It hydrolyzes fatty acids from S-acylated cysteine residues in proteins, showcasing depalmitoylating activity towards NRAS, DLG4/PSD95, and potentially MAP6. This activity is essential for the regulation of protein localization and function.

Therapeutic significance:

Understanding the role of Alpha/beta hydrolase domain-containing protein 17A could open doors to potential therapeutic strategies. Its enzymatic functions suggest a pivotal role in cellular signaling pathways, which, if modulated, could offer new avenues for treating diseases where protein palmitoylation is dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.